Buy Clomid Online

Fertility drugs, breast cancer, Clomid, follicle-stimulating hormone. A new study has presented an interesting finding: women who took fertility drugs and did not conceive a 10-plus week pregnancy had a reduced risk of breast cancer; however, women, who conceived a 10-plus week pregnancy had an increased risk of breast cancer. Researchers from the National Institute of Environmental Health Sciences in Bethesda, Maryland published their findings online on July 6 in the Journal of the National Cancer Institute. A research team led by Chunyuan Fei, PhD noted that ovulation-stimulating fertility drugs temporarily elevate estrogen levels in women, and estrogen is known to play an important role in breast cancer. They added that some studies have reported an increased breast cancer risk following infertility treatment; however, others have been inconclusive. The new study accessed data from the Two Sister Study, which is a case–control study (one sister diagnosed with breast cancer before age 50, one without). Of the 1,422 women with breast cancer and their corresponding breast-cancer-free sisters, 288 women reported using fertility drugs (clomiphene citrate (Clomid), follicle-stimulating hormone, or both). The researchers found that women using fertility drugs who did not conceive a 10-plus week pregnancy were at a statistically significant reduced risk of breast cancer compared to nonusers. In contrast, women using the drugs who conceived a 10-plus week pregnancy had a statistically significant increased risk of breast cancer compared to unsuccessfully treated women. However, this risk was comparable to nonusers. In an accompanying editorial, Louise A. Brinton, PhD noted that the reduction might only be related to clomiphene, which is a selective estrogen-receptor modulator similar to tamoxifen, which is a “well-established chemopreventative agent.”